Biomarkers Research | Proteomics, Genomics, Bioimaging Research

Description
Table of Contents
Major Market Players

The potential offered by biomarkers in shaping the outcomes of clinical trials, identifying new drug targets and developing diagnostic assays for detecting diseases early is immense, which has ensued in a large number of scientific publications coming out over the past two decades. Biomarker research encompasses widespread fields of discipline, which comprise drug discovery, toxicity, clinical markers of efficacy and therapeutic indicators, development of diagnostic assays and environmental pollutant exposure. The fields of epidemiology and toxicology have also made use of biomarkers in indicating exposure to a range of environmental substances. In such instances, the biomarker could be the substance itself, such as asbestos particles or nicotine-derived nitrosamine ketone (NNK) from tobacco, or a variation of the external substance processed by the body, such as a metabolite. Using biomarkers in species, such as aquatic animals and invertebrates can be helpful in determining levels and ranges of environmental pollutants.

Personalized medicine constitutes another facet that has been in an ever increasing mode, wherein genomic data are utilized for classifying subsets of patients that would respond to a specific line of therapy. The progression of biomarker research in ascertaining the basics of personalized medicine implies that the prospects of jointly developing drugs and biomarkers would be associated with identifying that section of the population that would garner the maximum benefit from that drug treatment. Developing such biomarkers requires expending considerable efforts and resources, which would enable in expanding the tasks accomplished by biomarkers in disease screening as surrogate endpoints and diagnostic indices.

Biomarker discovery techniques analyzed in this report include Bioimaging, Bioinformatics and Omics Technologies. On a broader geographic level, these technologies further drilled down to Bioimaging - Computed Tomography (CT), Magnetic Resonence Imaging (MRI), Ultrasound and Other; and Omics Technologies - Genomics, Metabolomics, Proteomics and Other. The study also explores the global market for therapeutic areas of biomarkers comprising Cardiology, Neurology, Oncology and Other.

The report reviews, analyses and projects the Biomarkers market for global and the regional markets including the United States, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 10 independent countries across Europe - France, Germany, Italy, Spain, Sweden, the United Kingdom; and Asia-Pacific - Australia, China, India and Japan. Accounting for a lion´s share of an estimated 47% in 2013, equating to US$18.9 billion, the United States leads the global market for Biomarkers. Growing at a robust compounded annual growth rate of 18.8% during the period 2013-2020, the global market is projected to touch US$63.2 billion.

This 350 pages, global market report includes 100 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the market value in US$ by geographic region, biomarker discovery techniques and therapeutic area. This report profiles 52 key global players and 70 major players across the United States - 34; Europe - 24; Asia-Pacific - 7 and Rest of World - 5. The research also provides the listing of the companies engaged in research & development, equipment manufacturing and supply of biomarkers. The global list of companies covers addresses, contact numbers and the website addresses of 245 companies.

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION
1.1 Product Outline
1.1.1 Biomarkers in Medicine
1.1.1.1 A History of Biomarkers
1.1.1.1.1 Philadelphia Chromosome
1.1.1.1.2 HIV Viral Load
1.1.1.1.3 HER-2 Gene and Receptor
1.1.1.2 Biomarkers for Diseases and Biomarkers for Drugs
1.1.1.3 Prerequisites of Biomarkers
1.1.1.4 Categorization of Biomarkers
1.1.1.4.1 Categorization of Biomarkers based on Types
1.1.1.5 Biomarkers in Drug Development
1.1.1.6 Biomarker in Diseases
1.1.2 Biomarker Discovery Technologies
1.1.2.1 Imaging-Based Biomarkers
1.1.2.1.1 Imaging Technologies
1.1.2.1.1.1 X-Rays
1.1.2.1.1.2 Computed Tomography (CT)
1.1.2.1.1.3 Positron Emission Tomography (PET)
1.1.2.1.1.4 Single Photon Emission Computed Tomography (SPECT)
1.1.2.1.1.5 Magnetic Resonance Imaging (MRI)
1.1.2.1.1.6 Ultrasound (US)
1.1.2.1.1.7 Others
1.1.2.2 Bioinformatics
1.1.2.3 Omics Technologies
1.1.2.3.1 Genomic Methods of Biomarker Discovery
1.1.2.3.2 Metabolomics Methods of Biomarker Discovery
1.1.2.3.3 Proteomic Methods of Biomarker Discovery
1.1.2.3.4 Other Omics Technologies for Biomarker Discovery
1.1.2.3.4.1 Lipidomics
1.1.2.3.4.2 Glycomics
1.1.2.3.4.3 Secretomics
1.1.3 Therapeutic Areas for Biomarkers
1.1.3.1 Cardiac Biomarkers
1.1.3.1.1 Measurement Applications of Cardiac Biomarkers
1.1.3.1.2 Classes of Cardiac Marker Tests
1.1.3.1.3 Biomarkers of Coronary Artery Disease
1.1.3.2 Neurological Disorder Biomarkers
1.1.3.3 Cancer Biomarkers
1.1.3.3.1 Cancer Biomarkers Defined
1.1.3.3.2 Functions of Biomarkers in Cancer Medicine
1.1.3.3.3 Functions of Biomarkers in Cancer Research
1.1.3.3.4 Categories of Cancer Markers
1.1.3.4 Other Therapeutic Areas for Biomarkers
1.1.3.4.1 Biomarkers of Diabetes
1.1.3.4.2 Biomarkers of Aging

2. KEY MARKET TRENDS
Detection of Cancer Biomarkers in Chemical Plume over Urine Samples Enabled by Mass Spectrometry
Identification of Early Stage Kidney Cancer Could be Facilitated through a Triumvirate of Biomarkers
Cancer Biomarker Detection Using Carbon-Nanotube Sensors
Development of Barrett´s Esophagus to Esophageal Adenocarcinoma Predicted through Novel Biomarkers
Metastatic Breast Cancer Detected by Circulating Tumor DNA
New Biomarker for Bone Marrow Cancer Identified
Detecting Breast Cancer Early and Monitoring Therapy with Blood Tests
Identification of Neuroblastomas with Sensitivity to BET Bromodomain Inhibitors Enabled through Biomarker
Earlier Diagnosis of Parkinson´s Disease Enabled through Blood-Based Biomarkers
Detection of Gliomas to be Assisted with a New Biomarker
New Biomarkers for Multiple Sclerosis
Developing Novel Therapies for Diabetes Facilitated with New Biomarkers
Trends in Approval for IVDs Based on Biomarkers
Developing Genomic Biomarkers Facilitated through Innovative Tissue Samples
Prospects of Enabling Earlier Cancer Diagnosis Offered by Innovative Technology
Possibilities for Cancer Therapy and Diagnosis Opened Up through MicroRNAs
Innovative MRI Technique Assists in Diagnosing Dementia Patients
Preventive Molecular Medicine and Metabolic Biomarkers
Predicting Cardiac Damage Induced Via Chemotherapy Earlier Facilitated by Biomarkers
Promising Proteomic Techniques in Biomarker Research for Prostate Cancer Biomarkers
Technology Innovation for Identifying Ulcerative Colitis Biomarkers
Success Rate of Clinical Trials of New Breast Cancer Drugs Enhanced with Biomarkers
Eye Movements as Biomarkers of Schizophrenia
New Biomarker Betters Prospects of Diagnosing Alzheimer´s Disease
Identifying and Treating Schizophrenia with Biomarkers
Early Disease Detection Facilitated Via Ultra-Sensitive Tests
Research and Development Efforts in Biomarkers: Some Notable Trends
Oral Cancer Detection Capacity Significantly Enhanced by Saliva Test
Autism Biomarkers Discovered

3. KEY MAJOR PLAYERS

4. KEY BUSINESS TRENDS
Unveiling of NanoString´s nCounter Elements™ General Purpose Reagents for Translational Research and Clinical Laboratories
Phase I Trial for VAL201, ValiRx´s Lead Compound
Researchers Identified Novel Blood Test for Alzheimer´s disease Diagnosis
Commercial Launch of Quanterix´s Simoa Technology
Strategic Alliance between Affymetrix and Massachusetts General Hospital for Oncology Biomarker Research
MolecularMD Corp. Acquires DDR2 Biomarker Commercial Rights
GEMMs Employed in the Development of Biomarkers for Molecular Subtypes Detection
C2N and Cambridge Isotope Laboratories Form Biomarkers Research and Supply Pact
Researchers Identified Advance Biomarkers to Detect Autism
Researchers at Emory Conduct Clinical Diagnosis Trial for Early Detection of PD
Genewiz and BeiGene Pair Up to Expedite the Discovery of Cancer Biomarkers
Collaboration of Fluidigm and Olink Bioscience to Discover Novel Protein Biomarkers
DaVita Labs, Myriad RBM Pair up for Protein Biomarkers Discovery
Results from Novel Biomarker Analyses of Vectibix® plus FOLFOX in mCRC Patients
FDA Approves bioM�rieux SA´s new THxID-BRAF Molecular Test
Oxford Cancer Biomarkers and AstraZeneca form Biomarker Discovery Pact
Agilent Technologies Join Forces with Applied Proteomics for Broadening Highly Multiplexed Protein Assays´ Potencies
OGT Acquired Rights for Advanced Development and Commercialization of microRNA Biomarkers for Prostate Cancer
KineMed Unveiled Kinetic Biomarkers for Neurological Disorders
Merck Partners with Luminex on Companion Diagnostic Development for Alzheimer´s Disease
ST2 Biomarker Detects High Dose Beta Blocker Therapy for Heart Failure Management
EMD Millipore Broadens its Biomarker Testing Service Competences
Unveiling of Horizon´s First Quantitative Multiplex Genomic DNA Reference Standard
Advanced Cell Diagnostics, The Johns Hopkins University Pair up for New Cancer Immunotherapy Biomarkers and Drug Targets Validation
Sengenics, Oxford Gene Technology Pair Up to Unveil Global Biomarker Discovery and Clinical Trial Immuno-Response Monitoring Service
Biotie Therapies´ tozadenant Receives Global License from UCB
Novel Personalized Medicine Partnership for Cancer headed by Caprion
Launch of RNAscope SpotStudio™ Image Analysis Software by Definiens and ACD
Collaboration between Covance and M2Gen® to Further Personalized Cancer Treatment
Initiation of Parkinson´s disease Biomarkers Program by NINDS of NIH
Issue of US Patent for Cardiac Troponin Biomarker Complex Detection of Axela
Discovery of New Biomarker and IL-6 Targeted Therapy in MS by BRI Researchers
Daiichi Sankyo and Amplimmune Form Protein Development Pact
Addition of Novel Biomarkers Deepen QIAGEN´s Personalized Healthcare Diagnostic Portfolio
Merck Establishes Strategic Alliance with GE Healthcare to Employ [18F] Flutemetamol in AD Diagnosis
Novel Genomic Biomarker Services Provided by EMD Millipore
Release of Biocartis´ DMAT Detection Platform for Biomarker Analysis
Myriad RBM Teamed Up with Sanofi and PHRI to Discover Protein Biomarkers for Diabetes
AVEO and Astellas Started Enrolling Patients in BATON-BC Clinical Study
GE Healthcare Announces the Consequences of the Early Economic Evaluation Studies
Multi-year Collaboration between Thermo Fisher Scientific and Fujirebio Inc. to Commercialize PCT Assay
Renewal of PCT Testing Collaboration between Thermo Fisher Scientific and bioM�rieux
Launch of Thermo Scientific Mass Spectrometric Immunoassay Pipette Tips
Ezose Sciences, Fast Forward Collaborate on MS Diagnostic Biomarkers Discovery
AstraZeneca and Roche Diagnostics Pair Up for Advanced Companion Diagnostics
Quintiles Establishes Oxford Cancer Biomarkers to Develop Oncology Biomarkers
Agilent Technologies and Gachon University Pair Up for Biomarkers Discovery
Commercial Release of UCB´s Neupro® in the US for PD and RLS treatment
Agilent Technologies, Gachon University Pair Up to Discover Oncology and Diabetes Biomarkers
VTT Partners with GE Healthcare on Novel AD Biomarkers Discovery
Agilent Technologies Plans to Establish Novel Neurometabolomics Research and Training Center in the City of Daegu
Bio-Rad Joined Forces with Myriad RBM on Multiplexed Immunoassay Kits
Neviah Genomics Established by Merck Serono and Compugen
Affymetrix and Massachusetts General Hospital Partner to Develop Biomarker Tests for Cancer
Commercial Launch of First Generation Animal Biomarker Assay from NextGen to Diagnose Brain Disorders
Unveiling of Aushon´s Cira™ Multiplex Immunoassay Platform
KineMed, GSK Pair up for Biomarker Research and Development
Commercial Launch of Novel Diagnostic Biomarker Assay for Brain Disorders
License Renewal of Genedata Expressionist® for Mass Spectrometry
Clarient, Insight Pair up to License ALK Gene Testing for Lung Cancer
Genomic Health Partners with OncoMed for NGS Diagnostic R&D based Biomarkers Discovery
HistoRx Inc. Uses its Patented AQUA Technology to Evaluate mRNA in Tissue
Abbott Receives Selective Rights for Genetic Biomarkers to Predict Specific Prostrate Cancer
Takeda and Metabolon Form Drug Discovery Pact
Commercial Launch of Novel Assay to Identify Biomarkers in Human Blood
Metabolon Establishes Alliance with Takeda on New Therapeutic Targets and Biomarkers Research
SomaLogic and the University of Washington Published the First Application Report of the SOMAscan™ Proteomic Assay Technology
Ezose Sciences, Hirosaki University Pair up to Discover Novel Oncology Biomarkers
Almac Collaborated with Affymetrix for Global Market Distribution of its Xcel™ Array
Unveiling of Bio-Rad´s Novel Bio-Plex Pro™ immunoassays to Discover Human Th17 Cytokines and Cancer Biomarkers
Bristol-Myers Squibb Partners with Meso Scale Discovery on AD Diagnostics Assays Development
First Commercial Mass Sequencing Laboratory of Chronix Biomedical Inaugurated
Epistem Joined Forces with Glaxosmithkline to Detect Fibrosis Biomarkers
HTG Partners with Sanofi US on Biomarkers Research
QIAGEN Broadens its Companion Diagnostics Portfolio by Receiving Genomic Biomarkers License
Bruker and SISCAPA Assay Technologies Together Published a Paper on SISCAPA-MALDI-TOF Mass Spectrometry
Agilent Technologies and Integrated Diagnostics Joined Forces on Proteomic Assays Development
EMD Millipore and Proteomics International Partner to Validate Diabetic Nephropathy Biomarkers
Biomnis, Trans-Hit Biomarkers Join Forces on Biomarker Research and Commercialization
Sanofi Establishes Alliance with Foundation Medicine to Detect Oncology Biomarkers and CDs
Research Collaboration between Ezose Sciences and Merck to Discover Biomarkers for Diabetes
Pacific Biomarkers Partnered with Clinigene International on Specialty Biomarker and High-end Clinical
Laboratory Services
Application of GeneNews´ Sentinel Principle® to Identify NPC Biomarkers
9-miRNA Biomarkers for Enhanced Pancreatic Cyst Patients´ Stratification
Exonhit and Pfizer Collaborates on Alzheimer´s disease Biomarker Research
Unveiling of Definiens´ Novel Quantitative Digital Pathology Product Suite
Research to Develop Novel Protein-based Technology at the Broad Institute Supported by Agilent
Definiens Plans to Launch Novel Generation of Products for Tissue-based Biomarker Research
Merck and BGI Joined Forces for Biomarkers and Genomic Technologies Discovery and Development
Successful Completion of Phase II multi-center Clinical Study by Siemens

5. GLOBAL MARKET OVERVIEW
5.1 Market Overview by Biomarker Discovery Technology
Bioimaging Market Overview by Imaging Modality
Omics Technology Market Overview by Segment
5.1.1 Biomarkers Discovery Technology Overview by Global Region
5.1.1.1 Bioimaging
5.1.1.2 Bioinformatics
5.1.1.3 Omics Technology
5.2 Market Overview by Biomarkers Therapeutic Area
5.2.1 Biomarkers Therapeutic Area Overview by Global Region
5.2.1.1 Cardiology
5.2.1.2 Neurology
5.2.1.3 Oncology
5.2.1.4 Other Disease Areas

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. THE UNITED STATES
1.1 United States Biomarkers Market Overview by Discovery Technology
United States Bioimaging Market Overview by Imaging Modality
United States Omics Technology Market Overview by Segment
1.2 United States Market Overview by Biomarkers Therapeutic Area
1.3 Major Market Players
Abbott Laboratories, Inc. (United States)
Affymetrix, Inc. (United States)
Agilent Technologies, Inc. (United States)
Altheadx, Inc. (United States)
Amgen, Inc. (United States)
Analytical Biological Services Inc. (United States)
Applied Neurosolutions, Inc. (United States)
Asuragen, Inc. (United States)
Aviva Biosciences Corporation (United States)
Banyan Biomarkers Inc. (United States)
Beckman Coulter, Inc. (United States)
Becton, Dickinson And Company (United States)
BG Medicine, Inc. (United States)
Bio-Rad Laboratories, Inc. (United States)
Bristol-Myers Squibb Company (United States)
Bruker Corporation (United States)
Celera Corporation (United States)
Charles River Laboratories International, Inc. (United States)
Clarient, Inc. (United States)
EMD Millipore Corporation (United States)
Genentech, Inc. (United States)
Genomic Health Inc. (United States)
Johnson & Johnson (United States)
Merck & Co., Inc. (United States)
Metabolon, Inc. (United States)
Myriad Genetics, Inc. (United States)
Perkinelmer Inc. (United States)
Pfizer, Inc. (United States)
Pharmaceutical Product Development, LLC. (United States)
Roche Diagnostics Corporation (United States)
Shimadzu Scientific Instruments, Inc. (United States)
Siemens Healthcare Diagnostics, Inc. (United States)
Sigma-Aldrich Corporation (United States)
Thermo Fisher Scientific Inc. (United States)

2. EUROPE
2.1 European Biomarkers Market Overview by Geographic Region
2.2 European Biomarkers Market Overview by Discovery Technology
European Bioimaging Market Overview by Imaging Modality
European Omics Technology Market Overview by Segment
2.2.1 Biomarkers Discovery Technology Overview by European Region
2.2.1.1 Bioimaging
2.2.1.2 Bioinformatics
2.2.1.3 Omics Technology
2.3 European Market Overview by Biomarkers Therapeutic Area
2.4 Major Market Players
ACE Biosciences A/S (Denmark)
Affibody AB (Sweden)
Agendia N.V. (Netherlands)
Alphalyse A/S (Denmark)
Ani Biotech Oy (Finland)
Astrazeneca Plc (United Kingdom)
Bayer AG (Germany)
Biocartis SA (Switzerland)
Biom�rieux SA (France)
Biosystems International (France)
Boehringer Ingelheim Gmbh (Germany)
Dako Denmark A/S (Denmark)
Decode Genetics (Iceland)
Epigenomics AG (Germany)
F. Hoffmann-La Roche Ltd. (Switzerland)
GE Healthcare Ltd. (United Kingdom)
Genedata AG (Switzerland)
Glaxosmithkline, Plc (United Kingdom)
Novartis AG (Switzerland)
Pamgene International BV (Netherlands)
Philips Healthcare (Netherlands)
Sanofi (France)
Siemens Healthcare (Germany)
UCB S.A. (Belgium)

2.5 European Biomarkers Market Overview by Country
2.5.1 France
2.5.2 Germany
2.5.3 Italy
2.5.4 Spain
2.5.5 Sweden
2.5.6 The United Kingdom
2.5.7 Rest of Europe

3. ASIA-PACIFIC
3.1 Asia-Pacific Biomarkers Market Overview by Geographic Region
3.2 Asia-Pacific Biomarkers Market Overview by Discovery Technology
Asia-Pacific Bioimaging Market Overview by Imaging Modality
Asia-Pacific Omics Technology Market Overview by Segment
3.2.1 Biomarkers Discovery Technology Overview by Asia-Pacific Region
3.2.1.1 Bioimaging
3.2.1.2 Bioinformatics
3.2.1.3 Omics Technology
3.3 Asia-Pacific Market Overview by Biomarkers Therapeutic Area
3.4 Major Market Players
Astellas Pharma Inc. (Japan)
Dr. Reddy´s Laboratories Limited (India)
GVK Biosciences Private Limited (India)
Human Metabolome Technologies Inc. (Japan)
Ocimum Biosolutions Ltd. (India)
Ranbaxy Laboratories Limited (India)
Takeda Pharmaceutical Company Limited (Japan)

3.5 Asia-Pacific Biomarkers Market Overview by Country
3.5.1 Australia
3.5.2 China
3.5.3 India
3.5.4 Japan
3.5.5 Rest of Asia-Pacific

4. REST OF WORLD
4.1 Rest of World Biomarkers Market Overview by Discovery Technology
Rest of World Bioimaging Market Overview by Imaging Modality
Rest of World Omics Technology Market Overview by Segment
4.2 Rest of World Market Overview by Biomarkers Therapeutic Area
4.3 Major Market Players
Compugen Ltd. (Israel)
Diagnocure Inc. (Canada)
Miraculins Inc. (Canada)
Nordion Inc. (Canada)
Rosetta Genomics Ltd. (Israel)

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA
1.1 Canada
1.2 United States

2. EUROPE
2.1 Belgium
2.2 Denmark
2.3 Finland
2.4 France
2.5 Germany
2.6 Iceland
2.7 Ireland
2.8 Italy
2.9 Norway
2.10 Spain
2.11 Sweden
2.12 Switzerland
2.13 The Netherlands
2.14 United Kingdom

3. ASIA-PACIFIC
3.1 Australia
3.2 China
3.3 India
3.4 Japan
3.5 Malaysia

4. REST OF WORLD
4.1 Israel

PART D: ANNEXURE
1. RESEARCH METHODOLOGY
2. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE
Chart 1: Trending of Global Market for Biomarker Identification by Omics Technology – Genomics, Metabolomics, Proteomics and Others in USD Million
Chart 2: Trending of Global Market for Biomarker Identification by Bioimaging Modality – CT, MRI, Ultrasound, and Others in USD Million
Chart 3: Global Biomarkers Market Analysis (2010-2020) in US$ Million
Chart 4: Global Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 5: Glance at 2010, 2015 and 2020 Global Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies
Chart 6: Global Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Imaging Modality – CT, MRI, Ultrasound and Other in US$ Million
Chart 7: Glance at 2010, 2015 and 2020 Global Bioimaging for Biomarker Discovery Market Share (%) by Imaging Modality – CT, MRI, Ultrasound and Other Technologies
Chart 8: Global Omics Technologies for Biomarker Discovery Market Analysis (2010-2020) by Segment – Genomics, Metabolomics, Proteomics and Other in US$ Million
Chart 9: Glance at 2010, 2015 and 2020 Global Omics Technologies for Biomarker Discovery Market Share (%) by Segment – Genomics, Metabolomics, Proteomics and Other
Chart 10: Global Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ Million
Chart 11: Glance at 2010, 2015 and 2020 Global Bioimaging for Biomarkers Discovery Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 12: Global Bioinformatics for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ Million
Chart 13: Glance at 2010, 2015 and 2020 Global Bioinformatics for Biomarkers Discovery Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 14: Global Omics Technologies for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ Million
Chart 15: Glance at 2010, 2015 and 2020 Global Omics Technology for Biomarkers Discovery Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 16: Global Biomarkers Market Analysis (2010-2020) by Therapeutic Area – Cardiology, Neurology, Oncology and Other in US$ Million
Chart 17: Glance at 2010, 2015 and 2020 Global Biomarkers Market Share (%) by Therapeutic Area – Cardiology, Neurology, Oncology and Other
Chart 18: Global Biomarkers Market Analysis (2010-2020) in Cardiology by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ Million
Chart 19: Glance at 2010, 2015 and 2020 Global Cardiology Market Share (%) of Biomarkers by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 20: Global Biomarkers Market Analysis (2010-2020) in Neurology by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ Million
Chart 21: Glance at 2010, 2015 and 2020 Global Neurology Market Share (%) of Biomarkers by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 22: Global Biomarkers Market Analysis (2010-2020) in Oncology by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ Million
Chart 23: Glance at 2010, 2015 and 2020 Global Oncology Market Share (%) of Biomarkers by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 24: Global Biomarkers Market Analysis (2010-2020) in Other Disease Areas by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ Million
Chart 25: Glance at 2010, 2015 and 2020 Global Other Disease Areas Market Share (%) of Biomarkers by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE
Chart 26: Projection of Prospective Regions in terms of Market Growth (CAGR) between 2010 and 2020 for Biomarkers by Geographic Region – Asia-Pacific, Europe and United States
Chart 27: Global Biomarkers Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ Million
Chart 28: Glance at 2010, 2015 and 2020 Global Biomarkers Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

THE UNITED STATES
Chart 29: United States Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 30: Glance at 2010, 2015 and 2020 United States Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies
Chart 31: United States Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Imaging Modality – CT, MRI, Ultrasound and Other in US$ Million
Chart 32: Glance at 2010, 2015 and 2020 United States Bioimaging for Biomarker Discovery Market Share (%) by Imaging Modality – CT, MRI, Ultrasound and Other Technologies
Chart 33: United States Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Segment – Genomics, Metabolomics, Proteomics and Other in US$ Million
Chart 34: Glance at 2010, 2015 and 2020 United States Omics Technology for Biomarker Discovery Market Share (%) by Segment – Genomics, Metabolomics, Proteomics and Other
Chart 35: United States Biomarkers Market Analysis (2010-2020) by Therapeutic Area – Cardiology, Neurology, Oncology and Other in US$ Million
Chart 36: Glance at 2010, 2015 and 2020 United States Biomarkers Market Share (%) by Therapeutic Area – Cardiology, Neurology, Oncology and Other

EUROPE
Chart 37: European Biomarkers Market Analysis (2010-2020) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe in US$ Million
Chart 38: Glance at 2010, 2015 and 2020 European Biomarkers Market Share (%) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe
Chart 39: European Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 40: Glance at 2010, 2015 and 2020 European Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies
Chart 41: European Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Imaging Modality – CT, MRI, Ultrasound and Other in US$ Million
Chart 42: Glance at 2010, 2015 and 2020 European Bioimaging for Biomarker Discovery Market Share (%) by Imaging Modality – CT, MRI, Ultrasound and Other Technologies
Chart 43: European Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Segment – Genomics, Metabolomics, Proteomics and Other in US$ Million
Chart 44: Glance at 2010, 2015 and 2020 European Omics Technology for Biomarker Discovery Market Share (%) by Segment – Genomics, Metabolomics, Proteomics and Other
Chart 45: European Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe in US$ Million
Chart 46: Glance at 2010, 2015 and 2020 European Bioimaging for Biomarkers Discovery Market Share (%) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe
Chart 47: European Bioinformatics for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe in US$ Million
Chart 48: Glance at 2010, 2015 and 2020 European Bioinformatics for Biomarkers Discovery Market Share (%) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe
Chart 49: European Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe in US$ Million
Chart 50: Glance at 2010, 2015 and 2020 European Omics Technology for Biomarkers Discovery Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World
Chart 51: European Biomarkers Market Analysis (2010-2020) by Therapeutic Area – Cardiology, Neurology, Oncology and Other in US$ Million
Chart 52: Glance at 2010, 2015 and 2020 European Biomarkers Market Share (%) by Therapeutic Area – Cardiology, Neurology, Oncology and Other

France
Chart 53: French Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 54: Glance at 2010, 2015 and 2020 French Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Germany
Chart 55: German Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 56: Glance at 2010, 2015 and 2020 German Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Italy
Chart 57: Italian Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 58: Glance at 2010, 2015 and 2020 Italian Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Spain
Chart 59: Spanish Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 60: Glance at 2010, 2015 and 2020 Spanish Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Sweden
Chart 61: Swedish Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 62: Glance at 2010, 2015 and 2020 Swedish Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

The United Kingdom
Chart 63: United Kingdom Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 64: Glance at 2010, 2015 and 2020 United Kingdom Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Rest of Europe
Chart 65: Rest of Europe Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 66: Glance at 2010, 2015 and 2020 Rest of Europe Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

ASIA-PACIFIC
Chart 67: Asia-Pacific Biomarkers Market Analysis (2010-2020) by Geographic Region – Australia, China, India, Japan and Rest of Asia-Pacific in US$ Million
Chart 68: Glance at 2010, 2015 and 2020 Asia-Pacific Biomarkers Market Share (%) by Geographic Region – Australia, China, India, Japan and Rest of Asia-Pacific
Chart 69: Asia-Pacific Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 70: Glance at 2010, 2015 and 2020 Asia-Pacific Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies
Chart 71: Asia-Pacific Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Imaging Modality – CT, MRI, Ultrasound and Other in US$ Million
Chart 72: Glance at 2010, 2015 and 2020 Asia-Pacific Bioimaging for Biomarker Discovery Market Share (%) by Imaging Modality – CT, MRI, Ultrasound and Other Technologies
Chart 73: Asia-Pacific Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Segment – Genomics, Metabolomics, Proteomics and Other in US$ Million
Chart 74: Glance at 2010, 2015 and 2020 Asia-Pacific Omics Technology for Biomarker Discovery Market Share (%) by Segment – Genomics, Metabolomics, Proteomics and Other
Chart 75: Asia-Pacific Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – Australia, China, India, Japan and Rest of Asia-Pacific in US$ Million
Chart 76: Glance at 2010, 2015 and 2020 Asia-Pacific Bioimaging for Biomarkers Discovery Market Share (%) by Geographic Region – Australia, China, India, Japan and Rest of Asia-Pacific
Chart 77: Asia-Pacific Bioinformatics for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – Australia, China, India, Japan and Rest of Asia-Pacific in US$ Million
Chart 78: Glance at 2010, 2015 and 2020 Asia-Pacific Bioinformatics for Biomarkers Discovery Market Share (%) by Geographic Region – Australia, China, India, Japan and Rest of Asia-Pacific
Chart 79: Asia-Pacific Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ Million
Chart 80: Glance at 2010, 2015 and 2020 Asia-Pacific Omics Technology for Biomarkers Discovery Market Share (%) by Geographic Region – Australia, China, India, Japan and Rest of Asia-Pacific
Chart 81: Asia-Pacific Biomarkers Market Analysis (2010-2020) by Therapeutic Area – Cardiology, Neurology, Oncology and Other in US$ Million
Chart 82: Glance at 2010, 2015 and 2020 Asia-Pacific Biomarkers Market Share (%) by Therapeutic Area – Cardiology, Neurology, Oncology and Other

Australia
Chart 83: Australian Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 84: Glance at 2010, 2015 and 2020 Australian Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

China
Chart 85: Chinese Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 86: Glance at 2010, 2015 and 2020 Chinese Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

India
Chart 87: Indian Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 88: Glance at 2010, 2015 and 2020 Indian Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Japan
Chart 89: Japanese Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 90: Glance at 2010, 2015 and 2020 Japanese Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Rest of Asia-Pacific
Chart 91: Rest of Asia-Pacific Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 92: Glance at 2010, 2015 and 2020 Rest of Asia-Pacific Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

REST OF WORLD
Chart 93: Rest of World Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million
Chart 94: Glance at 2010, 2015 and 2020 Rest of World Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies
Chart 95: Rest of World Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Imaging Modality – CT, MRI, Ultrasound and Other in US$ Million
Chart 96: Glance at 2010, 2015 and 2020 Rest of World Bioimaging for Biomarker Discovery Market Share (%) by Imaging Modality – CT, MRI, Ultrasound and Other Technologies
Chart 97: Rest of World Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Segment – Genomics, Metabolomics, Proteomics and Other in US$ Million
Chart 98: Glance at 2010, 2015 and 2020 Rest of World Omics Technology for Biomarker Discovery Market Share (%) by Segment – Genomics, Metabolomics, Proteomics and Other
Chart 99: Rest of World Biomarkers Market Analysis (2010-2020) by Therapeutic Area – Cardiology, Neurology, Oncology and Other in US$ Million
Chart 100: Glance at 2010, 2015 and 2020 Rest of World Biomarkers Market Share (%) by Therapeutic Area – Cardiology, Neurology, Oncology and Other

Abbott Laboratories, Inc.
ACE Biosciences A/S
Affibody AB
Affymetrix, Inc.
Agendia N.V.
Agilent Technologies, Inc.
Altheadx, Inc.
Amgen, Inc.
Analytical Biological Services Inc.
Astrazeneca Plc
Banyan Biomarkers Inc.
Bayer AG
Beckman Coulter, Inc.
Becton, Dickinson and Company
BG Medicine, Inc.
Biocartis SA
Biomerieux SA
Bio-Rad Laboratories, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Bruker Corporation
Celera Corporation
Charles River Laboratories International, Inc.
Clarient, Inc.
Compugen Ltd.
Decode Genetics
Dr. Reddy's Laboratories Limited
EMD Millipore Corporation
Epigenomics AG
F. Hoffmann-La Roche Ltd.
GE Healthcare Ltd.
Genedata AG
Glaxosmithkline, Plc
Johnson & Johnson
Merck & Co., Inc.
Nordion Inc.
Novartis AG
Perkinelmer Inc.
Pfizer, Inc.
Pharmaceutical Product Development, LLC.
Philips Healthcare
Ranbaxy Laboratories Limited
Roche Diagnostics Corporation
Rosetta Genomics Ltd.
Sanofi
Shimadzu Scientific Instruments, Inc
Siemens Healthcare
Siemens Healthcare Diagnostics, Inc.
Sigma-Aldrich Corporation
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc
UCB S.A.